Dataset from Phase IV Open Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-Mumps-Rubella (MMR) Vaccine When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.

To evaluate the safety and immunogenicity of GSK Biologicals' live attenuated MMR vaccine (Priorix) in a local population in Singapore. The vaccine was administered as a single dose to healthy children (12-18 months of age) and blood samples were collected at two time points (before vaccination and after vaccination).

本数据集旨在评估葛兰素史克生物制品（GSK Biologicals）研发的减毒活麻疹-腮腺炎-风疹联合疫苗（Measles, Mumps, Rubella Vaccine，简称MMR，商品名Priorix）在新加坡本地人群中的安全性与免疫原性。该疫苗以单剂次给药方式施予12至18月龄的健康儿童，并在接种前与接种后两个时间节点采集血液样本。